- $40.35m
- $28.80m
- $69.30m
- 38
- 53
- 15
- 27
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.42 | ||
| Price to Tang. Book | 1.51 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.58 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -48.07% | ||
| Return on Equity | -159.87% | ||
| Operating Margin | -49.23% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 18.21 | 29.46 | 41.42 | 58.45 | 69.3 | 85.54 | 105.21 | 35.02% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
Directors
- Douglas Evans NEC (56)
- Antony Koblish PRE (55)
- Roberto Cuca CFO (54)
- Ellis Greenhalgh CTO (53)
- Kurt Azarbarzin IND (58)
- Vince Burgess IND (56)
- Lisa Colleran IND (63)
- John Nosenzo IND (63)
- Federica O'brien IND (63)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 17th, 2012
- Public Since
- November 8th, 2019
- No. of Shareholders
- 58
- No. of Employees
- 209
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 39,554,771
- Address
- 1 Great Valley Parkway, Suite 24, MALVERN, 19355
- Web
- https://www.telabio.com/
- Phone
- +1 4843202930
- Auditors
- KPMG LLP
Upcoming Events for TELA
Q1 2025 TELA Bio Inc Earnings Call
TELA Bio Inc Annual Shareholders Meeting
TELA Bio Inc Annual Shareholders Meeting
Q2 2025 TELA Bio Inc Earnings Release
Similar to TELA
908 Devices
NASDAQ Global Market
Alpha Teknova
NASDAQ Global Market
Anteris Technologies Global
NASDAQ Global Market
AtriCure
NASDAQ Global Market
Beta Bionics
NASDAQ Global Market
FAQ
What is the TELA Bio share price?
As of Today at 23:38 UTC, shares in TELA Bio are trading at $1.02. This share price information is delayed by 15 minutes.
How has the TELA Bio share price performed this year?
Shares in TELA Bio last closed at $1.02 and the price had moved by -77.97% over the past 365 days. In terms of relative price strength the TELA Bio share price has underperformed the S&P500 Index by -80.13% over the past year.
What are the analyst and broker recommendations for TELA Bio?
The overall consensus recommendation for TELA Bio is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the TELA Bio dividend yield?
TELA Bio does not currently pay a dividend.
Does TELA Bio pay a dividend?
TELA Bio does not currently pay a dividend.
When does TELA Bio next pay dividends?
TELA Bio does not currently pay a dividend.
How do I buy TELA Bio shares?
To buy shares in TELA Bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of TELA Bio?
As of the previous close price of $1.02, shares in TELA Bio had a market capitalisation of $40.35m.
Where are TELA Bio shares listed?
Here are the trading details for TELA Bio:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: TELA
What kind of share is TELA Bio?
Based on an overall assessment of its quality, value and momentum TELA Bio is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a TELA Bio share price forecast for 2025?
The analyst consensus target price for shares in TELA Bio is $5.80. That is 468.63% above the last closing price of $1.02.
Analysts covering TELA Bio currently have a consensus Earnings Per Share (EPS) forecast of -$0.65 for the next financial year.
Find out moreWhat is the trend in the TELA Bio share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like TELA Bio. Over the past six months, its share price has underperformed the S&P500 Index by -64.67%.
As of the last closing price of $1.02, shares in TELA Bio were trading -61.37% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the TELA Bio PE Ratio?
The TELA Bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.02.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of TELA Bio?
TELA Bio's management team is headed by:
- Douglas Evans - NEC
- Antony Koblish - PRE
- Roberto Cuca - CFO
- Ellis Greenhalgh - CTO
- Kurt Azarbarzin - IND
- Vince Burgess - IND
- Lisa Colleran - IND
- John Nosenzo - IND
- Federica O'brien - IND